At Incyte, our research is grounded in the relentless pursuit of scientific excellence and the conviction that the advancement of basic science can drive the discovery of innovative medicines for patients. Our world-class researchers are focused on transforming the treatment of cancer and inflammatory and autoimmune conditions, and are advancing a diversified portfolio of clinical candidates.

OVERVIEW OF OUR PORTFOLIO

Molecular Targets
17

Clinical Candidates
19

Portfolio

Filter by:
Filters

Updated as of February 13, 2020

1. Jakafi marketed by Incyte in the US; ruxolitinib licensed to Novartis ex-US 2. Adults with intermediate or high-risk myelofibrosis 3. Adults with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea 4. Adults and pediatric patients 12 years and older with steroid-refractory acute graft-versus-host disease 5. European rights to Iclusig licensed from ARIAD 6. In collaboration with MacroGenics  7. Co-development with Calithera 8. Discovery collaboration with Agenus 9. In collaboration with Merus 10. Worldwide rights to baricitinib licensed to Lilly: approved as Olumiant in multiple territories globally for certain patients with moderate to severe rheumatoid arthritis 11. Worldwide rights to capmatinib licensed to Novartis

The efficacy and safety of the investigational compounds discussed have not been established. There is no guarantee that these compounds will become commercially available for the use(s) under investigation.

Clinical Trials

We have numerous clinical trials underway across Oncology and Inflammation & Autoimmunity research areas. Incyte-sponsored studies can be found at www.IncyteClinicalTrials.com.

Incyte also supports significant independent research aimed at advancing the study of our products. A team of professionals scrutinizes all proposals submitted to Incyte for scientific merit and alignment with Incyte’s research goals. If you are interested in submitting a research proposal, please visit our online portal at iir.incyte.com.

Learn more about our target molecules currently in clinical development

For questions concerning Investigator Initiated Research conducted outside of the US, please contact Incyte at Global_IIR@incyte.com.

For questions concerning Investigator Initiated Research conducted in the US, please contact Incyte at US_IIR@incyte.com.